Al-Kharashi Abdullah S, Aldibhi Hassan, Al-Fraykh Hamad, Kangave Dustan, Abu El-Asrar Ahmed M
Department of Ophthalmology, College of Medicine, King Saud University, Riyadh 11411, Saudi Arabia.
Int Ophthalmol. 2007 Apr-Jun;27(2-3):201-10. doi: 10.1007/s10792-007-9062-9. Epub 2007 Apr 14.
To identify prognostic factors for final visual outcome, development of complications, and recurrent inflammation in patients with Vogt-Koyanagi-Harada (VKH) disease.
All patients diagnosed with acute uveitis associated with VKH disease at the King Khaled Eye Specialist Hospital and King Abdulaziz University Hospital between January 1999 and February 2004 were reviewed. Data collected included age, gender, initial and final visual acuities, clinical findings at presentation, interval between onset of disease and starting treatment, treatment received, complications, number of recurrences, extraocular manifestations, and duration of follow-up period.
Sixty-eight patients were identified. There were 51 (75%) females and 17 (25%) males with a mean age of 25.04 +/- 10.28 years (range 7-55 years). The mean follow-up period was 34.4 +/- 20.1 months (range 8-62 months). The following factors were significantly associated with final visual acuity of 20/20 by univariate analysis: good initial visual acuity of better than 20/200 (p = 0.0415), absence of posterior synechiae of the iris at presentation (p = 0.0106), use of systemic corticosteroids for longer than nine months (p = 0.0479), slow tapering of systemic corticosteroids (p = 0.0024), absence of complications (p < 0.001), and absence of extraocular manifestations (p = 0.0124). Logistic regression analysis identified the use of systemic corticosteroids for longer than nine months to be associated with final visual acuity of 20/20 [odds ratio = 3.4; 95% confidence interval (CI) = 1.14-10.1]. The following factors were significantly associated with the development of complications by univariate analysis: age older than 18 years (p = 0.0161), initial visual acuity of 20/200 or worse (p = 0.0011), and presence of posterior synechiae of the iris at presentation (p = 0.0453). Factors identified after logistic regression analyses were age older than 18 years (odds ratio = 3.3; 95% CI = 1.33-8.17), and presence of posterior synechiae of the iris at presentation (odds ratio = 3.42; 9% CI = 1.38-8.47). Initial visual acuity of better than 20/200 was significantly associated with a lower risk of developing complications (odds ratio = 0.283; 95% CI = 0.129-0.629). The following factors were significantly associated with recurrent inflammation of three times or more by univariate analysis: initial visual acuity of 20/200 or worse (p = 0.0179), anterior chamber reaction of more than 2+ at presentation (p < 0.001), rapid tapering of systemic corticosteroids (p < 0.001), and development of extraocular manifestations (p = 0.0277).
Clinical findings at presentation, duration and method of tapering of systemic corticosteroids, and development of extraocular manifestations are significantly associated with final visual acuity, development of ocular complications, and recurrent inflammation. The development of ocular complications was significantly associated with a worse final visual acuity.
确定伏格特-小柳-原田(VKH)病患者最终视力结果、并发症发生情况及炎症复发的预后因素。
回顾了1999年1月至2004年2月在沙特国王哈立德眼科专科医院和阿卜杜勒阿齐兹国王大学医院诊断为与VKH病相关的急性葡萄膜炎的所有患者。收集的数据包括年龄、性别、初始和最终视力、就诊时的临床表现、疾病发作与开始治疗的间隔时间、接受的治疗、并发症、复发次数、眼外表现以及随访期的持续时间。
共确定68例患者。其中女性51例(75%),男性17例(25%),平均年龄25.04±10.28岁(范围7 - 55岁)。平均随访期为34.4±20.1个月(范围8 - 62个月)。单因素分析显示,以下因素与最终视力达到20/20显著相关:初始视力优于20/200(p = 0.0415)、就诊时虹膜无后粘连(p = 0.0106)、全身使用皮质类固醇超过9个月(p = 0.0479)、全身皮质类固醇缓慢减量(p = 0.0024)、无并发症(p < 0.001)以及无眼外表现(p = 0.0124)。逻辑回归分析确定全身使用皮质类固醇超过9个月与最终视力达到20/20相关[比值比 = 3.4;95%置信区间(CI) = 1.14 - 10.1]。单因素分析显示,以下因素与并发症的发生显著相关:年龄大于18岁(p = 0.0161)、初始视力为20/200或更差(p = 0.0011)以及就诊时虹膜有后粘连(p = 0.0453)。逻辑回归分析后确定的因素为年龄大于18岁(比值比 = 3.3;95% CI = 1.33 - 8.17)以及就诊时虹膜有后粘连(比值比 = 3.42;9% CI = 1.38 - 8.47)。初始视力优于20/200与并发症发生风险较低显著相关(比值比 = 0.283;95% CI = 0.129 - 0.629)。单因素分析显示以下因素与炎症复发三次或更多次显著相关:初始视力为20/200或更差(p = 0.0179)、就诊时前房反应超过2+(p < 0.001)、全身皮质类固醇快速减量(p < 0.001)以及出现眼外表现(p = 0.0277)。
就诊时的临床表现、全身皮质类固醇的使用时间和减量方法以及眼外表现的出现与最终视力、眼部并发症的发生以及炎症复发显著相关。眼部并发症的发生与更差的最终视力显著相关。